NCT04129775View on ClinicalTrials.gov

OTO-413 in Subjects With Speech-in-Noise Hearing Impairment

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

September 5, 2022

Study Completion Date

September 5, 2022

Conditions
Sensorineural Hearing Loss
Interventions
DRUG

OTO-413

Single intratympanic injection of Brain-Derived Neurotrophic Factor (BDNF)

DRUG

Placebo

Single intratympanic injection of placebo

Trial Locations (8)

23507

Eastern Virginia Medical School, Department of Otolaryngology, Norfolk

27103

Piedmont Ear, Nose & Throat Associates, Winston-Salem

33024

Research Centers of America, Hollywood

33156

South Florida ENT Associates or Research Centers of America, Miami

33612

University of South Florida, Tampa

40220

Advanced ENT and Allergy, PLLC, Louisville

80923

Colorado Otolaryngology Associates LLC dba Colorado ENT & Allergy, Colorado Springs

84107

JBR Clinical Research, Salt Lake City

Sponsors

Lead Sponsor

Otonomy, Inc.
All Listed Sponsors
lead

Otonomy, Inc.

INDUSTRY